Deutsche Bank AG Takes Position in Illumina, Inc. $ILMN

Deutsche Bank AG purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, Holdings Channel reports. The fund purchased 392,417 shares of the life sciences company’s stock, valued at approximately $68,999,000.

Other large investors have also modified their holdings of the company. Perigon Wealth Management LLC bought a new stake in Illumina in the 2nd quarter valued at about $1,004,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Illumina during the 2nd quarter valued at about $30,501,000. OneDigital Investment Advisors LLC bought a new position in Illumina in the 2nd quarter worth about $252,000. Plato Investment Management Ltd bought a new position in Illumina in the 2nd quarter worth about $948,000. Finally, Baxter Bros Inc. acquired a new stake in shares of Illumina in the second quarter valued at approximately $295,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Transactions at Illumina

In related news, Director Keith A. Meister sold 283,269 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $199.61, for a total transaction of $56,543,325.09. Following the completion of the transaction, the director owned 2,089,425 shares of the company’s stock, valued at $417,070,124.25. This trade represents a 11.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,416,384 shares of company stock valued at $256,164,151 over the last three months. 2.90% of the stock is owned by company insiders.

Illumina Stock Up 4.0%

ILMN stock opened at $213.24 on Friday. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.32. The company has a market capitalization of $32.20 billion, a price-to-earnings ratio of 39.78, a price-to-earnings-growth ratio of 2.89 and a beta of 1.45. The firm’s 50-day moving average is $186.84 and its two-hundred day moving average is $151.97. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period last year, the firm posted $1.19 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price target on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday, August 3rd. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a report on Thursday, May 14th. Guggenheim raised their target price on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Citigroup lifted their target price on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Finally, JPMorgan Chase & Co. boosted their price target on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.